Aspira is Transforming Women's Health

with Innovative Solutions

Aspira is led by an experienced team of business, medical and scientific professionals with a passion for improving health outcomes for women.

Meet our Leadership Team

About Aspira Women's Health

Our Mission

Aspira Women's Health is helping transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products Ova1® and Overa® detect the risk of ovarian malignancy in women with adnexal masses. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.

Learn More

Most Recent Press Releases


  • Aspira Women’s Health Announces Preliminary Second Quarter 2024 OvaSuite Product Volume and Highlights

    Preliminary OvaWatch® volume during Q2 2024 grew 24% over the prior quarter to 1,307 units Preliminary OvaSuiteSM volume during Q2 2024 grew 11% over the prior quarter to 6,471 units  AUSTIN, Texas, July 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused…

  • Aspira Women’s Health Announces Closing of $1.9 Million Private Placement Equity Financing

     July 09, 2024 12:12 ET  AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of…

  • View all Press Releases